DiaGenic reports final results from an exploratory study that examines
the agreement between gene expression in blood and brain amyloid PET
imaging. In a patient population of 144 patients, a gene expression
biomarker was identified that demonstrated an agreement of 69% with
brain amyloid PET imaging.
The primary goal of this exploratory study was to identify a gene
expression biomarker which detects whether an individual has normal or
elevated levels of amyloid in the brain as determined by brain amyloid
PET imaging. The subsequent goal was to develop an IVD multivariate
index assay test, AMYtectT. The study included 144 patients from
clinical centers coordinated by Lund University in Sweden, of which 118
were diagnosed with suspected mild cognitive impairment and 26 were
healthy controls. Blood samples were collected and brain amyloid PET
scans using GE Healthcare's investigational [18F] Flutemetamol tracer
were performed for all patients. The results show an agreement of 69%
between gene expression in blood and brain amyloid using PET imaging as
the reference.
"This study showed a significant correlation between a gene expression
biomarker candidate and brain amyloid PET imaging. This is a novel and
encouraging result in the quest to identify a blood test to screen for
early Alzheimer's patients. However, the correlation reached with the
current biomarker panel is not sufficient to warrant clinical
development of AMYtect", said Paul de Potocki, CEO at DiaGenic.
For more information, contact:
Paul de Potocki, CEO at DiaGenic, telephone: +47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative diagnostic company that seeks to create value
for patients, partners and investors by developing patient friendly in
vitro diagnostic (IVD) products for early detection of diseases. The
company's proprietary concept implies that a disease evokes systemic
responses in the blood unique for the disease, and which can be measured
by using blood samples. DiaGenic is a world leader in identifying gene
expression signatures in blood and is focused on the development of IVD
biomarker products in the field of Alzheimer's disease. The company
protects its technology through an extensive patent portfolio. DiaGenic
is listed on the Oslo Stock Exchange.